
Erasca reports strong Phase 1 results for ERAS-0015 in KRAS-mutant cancers, plans Phase 3 trials in 2027.
Erasca announced positive Phase 1 data for its pan-RAS molecular glue ERAS-0015, showing notable response rates in heavily pretreated KRAS-mutant pancreatic and lung cancers with good safety. The company plans to start potentially registration-enabli...


